transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a Type 2 diabetic rat model. Am J Physiol Heart Circ Physiol 292: H1204 -H1207, 2007. First published September 29, 2006; doi:10.1152/ajpheart.00892.2006.-The Otsuka Long-Evans Tokushima fatty rat is an animal model of Type 2 diabetes mellitus (DM), which is characterized by diastolic dysfunction associated with decreased sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA2a). The aim of this study was to examine whether gene transfer of SERCA2a can influence coronary blood flow and cardiomyocyte diameter in this model. DM rats were injected with adenovirus carrying SERCA2a (DMϩSERCA) or ␤-galactosidase gene (DMϩ␤Gal). Coronary blood flow was measured in cross-circulated excised hearts 3 days after infection. Although in all groups coronary blood flow remained unchanged even if left ventricular (LV) volume or intracoronary Ca 2ϩ infusion was increased, the DMϩSERCA group showed a sustained increase in coronary blood flow compared with the other groups. This result suggests that the sustained high coronary blood flow is a specific response in SERCA2a-overexpressed hearts. Although the LV weight-to-body weight ratio (LV/BW) and cardiomyocyte diameter were higher in the DM and DMϩ␤Gal groups than in the non-DM group, in the DMϩSERCA group, these measurements were restored to non-DM size. The percentages of collagen area in the three DM groups was significantly higher than results shown in non-DM rats, and there were no significant differences in collagen area percentage among the three DM groups. These results suggest that a lowered LV/BW by SERCA2a overexpression is due mainly to reduced size of cardiomyocytes without any changes in collagen area percentage. In conclusion, in DM failing hearts, SERCA2a gene transfer can increase coronary blood flow and reduce cardiomyocyte size without reduction in collagen production. gene therapy; heart failure; diabetes mellitus; cardiomyocyte hypertrophy THE OTSUKA LONG-EVANS TOKUSHIMA fatty (OLETF) rat was established as a model of human Type 2 diabetes mellitus (DM) (8). This DM rat is characterized by left ventricular (LV) diastolic dysfunction and a slow LV relaxation rate with decreased sarcoplasmic reticulum (SR)-ATPase (SERCA2a) (1, 11).
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The key role of Ca 2ϩ in relaxation of cardiac or vascular smooth muscles is well established. The main site for dynamic control of intracellular Ca 2ϩ concentration is the SR, which releases Ca 2ϩ into the cytoplasm during contraction and takes it up during relaxation by the SERCA2 pump. Thus the removal of Ca 2ϩ from the cytoplasm is governed mainly by SERCA2. Cardiac muscles express SERCA2a, whereas vascular smooth muscles express SERCA2b and, to a lesser extent, SERCA2a (6, 9, 10, 15) . In failing rat hearts (6, 10, 15) and in hypercholesterolemic rabbit and mouse aorta smooth muscle (2, 3) , the abnormal Ca 2ϩ handling due to the SERCA2 protein reduction contributes to the impaired relaxation.
Our group (6, 10) has previously shown that global cardiac gene transfer of SERCA2a improves contractile function and energetic state (as measured by phosphocreatine-to-ATP ratio) in aortic-banded rats. Moreover, SERCA2a overexpression improved anterior wall thickening and reduced ventricular arrhythmias in a rat model of ischemia (5) . Most recently, our group (15) has demonstrated that, in OLETF DM hearts, the high oxygen cost of LV contractility can be restored to non-DM levels by SERCA2a gene transfer. The aim of this study was to examine how transcoronary gene transfer of SERCA2a can influence coronary blood flow (CBF) and cardiomyocyte diameter (CMD) in the DM rat model. Thus, in the present study, we analyzed both CBF in response to LV mechanical or Ca 2ϩ loading and histological data [CMD and collagen area percentage (CAP)] in 15 of the same hearts that our group recently studied (15) and one DM heart with adenoviral ␤-galactosidase transfer. We report here that, in DM failing hearts, SERCA2a gene transfer can increase CBF and decrease CMD without reduction in collagen production.
MATERIALS AND METHODS
Animals and adenoviral vectors. All animal procedures were performed with the approval of the Animal Care Committee of Massachusetts General Hospital and in accordance with the National Institute of Health's Guide for the Care and Use of Laboratory Animals. Twelve male DM OLETF and four normal non-DM Long-Evans Tokushima Otsuka rats were used. DM rats (70 -80 wk old) with ϳ300 mg/dl of blood glucose concentration were randomized into three groups [group without gene transfer (DM), group with SERCA2a transfer (DMϩSERCA), and group with ␤-galactosidase transfer (DMϩ␤Gal); n ϭ 4 in each group]. Recombinant adenoviral vectors were used with cytomegalovirus-driven expression cassettes for SERCA2a (Ad.SERCA2a) or ␤-galactosidase (Ad.␤Gal) (5, 6, 10, 15) . Ad.SERCA2a and Ad.␤Gal had concentrations of 6.2 ϫ 10 10 and 4.8 ϫ 10 10 pfu/ml, respectively.
Transcoronary gene transfer.
The transcoronary adenoviral delivery system has been described previously by our group (5, 6, 10, 15) . Briefly, after the rats were anesthetized and a thoracotomy was performed, a 22-gauge catheter containing 200 l of adenovirus and 50 l of adenosine (3 mg/ml) was advanced from the apex of the LV to the aortic root. The aorta and main pulmonary artery were clamped for 30 s distal to the site of the catheter, and the solution was injected. The chest was then closed, and the animals were allowed to recover. The rats underwent CBF analysis in a cross-circulated excised heart 3 days after the adenoviral gene transfer.
Cross-circulated heart preparation. The cross-circulated, bloodperfused, excised heart preparation has been described previously by our group (12) . Briefly, in each experiment, two male (500 -650 g) Wistar rats (blood supplier and metabolic supporter) and one DM or non-DM rat (heart donor) were anesthetized with pentobarbital sodium (50 mg/kg ip) and intubated and heparinized (1,000 U iv). In the rat used as the metabolic supporter, the common carotid arteries and the right external jugular vein were cannulated and connected to the arterial and venous cross-circulation tubing, respectively. The arterial and venous cross-circulation tubes from the support rat were cannulated into the brachiocephalic artery and the right ventricle (RV) via the superior vena cava, respectively, of the heart donor rat. In the excised beating heart maintained at 37°C, a thin latex balloon, connected to a pressure transducer for measuring LV pressure, was inserted into the LV and primed with water. Intraballoon water volume was changed from 0 to 0.1 ml by 0.025 ml. Heart rate was maintained constant at 300 beats/min by electrical pacing of the right atrium. Total CBF was continuously measured with an ultrasonic flowmeter (model T206; Transonic System), in which the inline flowprobe was placed in the middle of the coronary venous drainage tubing from the RV. LV thebesian flow was negligible. Systemic arterial blood pressure of the metabolic supporter rat served as coronary perfusion pressure, which was almost constant (mean of ϳ90 mmHg) throughout the experiment. Myocardial oxygen consumption (V O2) was obtained as the product of CBF and arteriovenous oxygen content difference (AVOD). Arterial pH, PO2, and PCO2 of the support rat and perfused blood were maintained within their physiological ranges with supplemental oxygen and sodium bicarbonate throughout the experiment. Physiological data were obtained at five different LV volumes changed with a step of 0.025 ml, without any inotropic interventions (control volume-loading run). After the control volume-loading run, Ca 2ϩ inotropism run was performed at a given midrange LV volume, i.e., at 0.05 ml of intraballoon water, by intracoronary infusion of 1% CaCl 2 solution. The infusion rate was increased step-wise from 2 to 6 ml/h. Data sampling was started 4 min after the onset of Ca 2ϩ infusion. Steady-state V O2 was reached 2-3 min after change of LV volume and 4 min after change of the infusion rate. In each steady state, data were sampled at 500 Hz for 2 s simultaneously, and the sampling was usually repeated three times at intervals of 0.5-1 min.
Histological analysis. LV specimens, obtained after the crosscirculation studies, were fixed with 10% formalin and embedded in paraffin. Sections (3 m thick) were stained with hematoxylin-eosin to determine CMD or with Azan-Mallory to assess CAP. In longitudinally oriented cardiomyocytes, transnuclear width was measured as CMD. Digital photographs were taken at six sites on each AzanMallory section. Interstitial/perivascular collagen area and myocyte area were determined separately by counting the computerized pixels with the use of NIH Image.
Western blot for SERCA2a protein.
Lysates from the hearts were matched for protein concentration and then separated by SDS-PAGE and transferred to nitrocellulose membranes. For immunoreaction, the blots were incubated with SERCA2a antibodies followed by detection with enhanced chemiluminescence.
Statistics. Data are expressed as means Ϯ SD. Multiple comparisons were performed by ANOVA, followed by a Student-NewmanKeuls post hoc test. Statistical significance was accepted at the level of P Ͻ 0.05.
RESULTS

Decrease in CMD by SERCA2a overexpression.
All groups showed no difference in body weight (BW) and RV weightto-BW ratio as recently reported by our group (15) . On the other hand, the DM and DMϩ␤Gal groups showed a significant increase in LV-to-BW ratio (Fig. 1A ) and in CMD (Fig. 1B) . In DMϩSERCA rats, however, LV/BW and CMD were as small as results shown in the non-DM group. CAP results in the three DM groups were similar, although signifi- cantly higher than those shown in non-DM (Fig. 1C) . These results suggest that lowered LV/BW in DMϩSERCA animals is mainly due to reduced size of cardiomyocytes.
Increase in CBF by SERCA2a overexpression. Although mean coronary perfusion pressure was almost constant in all hearts, DMϩSERCA rats showed a sustained increase in basal CBF under mechanically unloaded (i.e., free of intraballoon water) contraction without any inotropic interventions, compared with other groups (Fig. 1D) , and thus a significant decrease in coronary vascular resistance. The increase either in the LV volume in control volume-loading run or in the Ca 2ϩ infusion rate in Ca 2ϩ inotropism run induced not only increased mechanical performance [upward-shifted end-systolic pressure-volume relation or increased end-systolic pressure at 0.05 ml of intraballoon water, as previously reported in the same hearts (15)] but also increased AVOD with no change in CBF ( Fig. 2A) and hence increased myocardial V O 2 (Fig. 2B) . Therefore, the V O 2 could be determined primarily by AVOD (Fig. 2C) . Thus the CBF in all groups remained unchanged, even in control volume-loading run and Ca 2ϩ inotropism run. DMϩSERCA rats showed a significantly higher CBF in both runs (P Ͻ 0.05), as well as higher basal CBF, compared with other groups [mean CBF in control volume-loading run (n ϭ 4 in each group) as follows: for non-DM, 2.41 Ϯ 0. ]. The unchanged CBF in all hearts suggests that the vascular tone is preserved irrespective of the increase in LV mechanical or Ca 2ϩ loading, and the sustained high CBF is a specific response in SERCA2a-overexpressed hearts. Finally, SERCA2a protein expression, which was decreased in DM and DMϩ␤Gal rats, was restored to non-DM levels by SERCA2a gene transfer (Fig. 3) .
DISCUSSION
In this study, we found that transcoronary gene transfer of SERCA2a can increase CBF and reduce cardiomyocyte size in DM hearts.
Our group (6, 10, 16) has previously shown that gene transfer of SERCA2a improves both systolic and diastolic function in failing hearts (due to pressure overload) and diastolic function in aging rats. However, in these studies, it was not clear whether the improvement in contractile function was accompanied by changes in cardiomyocyte size and resolution of fibrosis. In the present study, the lowered LV/BW by SERCA2a overexpression in DM hearts (which have combined systolic and diastolic dysfunction) appears to be mainly due to reduced size of cardiomyocytes but not to reduced CAP. Likewise, lowered LV/BW and reduced CMD were found in a postinfarct rat model following gene transfer of phospholamban mutant, which must have activated the function of SERCA2a (7) . Although many intracellular signaling pathways may contribute to CMD reduction by SERCA2a overexpression, one possible explanation is as follows: increased SERCA2a activity achieves the decrease in diastolic intracel- lular Ca 2ϩ concentration by increasing uptake into the SR, thereby possibly inducing inactivation of a Ca 2ϩ -regulated phosphatase, calcineurin, which plays a central role in transducing environmental signals that control gene expression and hypertrophic growth in cardiac muscles (13) .
One possible explanation for increased CBF by SERCA2a overexpression is as follows. The DMϩSERCA group, as recently reported by our group (15) , showed systolic/diastolic LV function superior to normal LV function observed in non-DM rats (i.e., the increased end-systolic pressure at 0.1 ml of intraballoon water and the decreased end-diastolic pressure at 0.1 ml of intraballoon water), although the DM and DMϩ␤Gal groups showed LV dysfunction. This superior LV relaxation induced by SERCA2a transfer may increase CBF via well-dilated coronary vessels due to a more efficient relaxation because CBF occurs primarily during the diastolic phase. This is supported by the recent finding that impaired coronary hemodynamics is associated with ventricular dysfunction in salt-loaded spontaneously hypertensive rats (17) . However, we cannot rule out another possibility that exogenous SERCA2a gene may be expressed not only in cardiac but in vascular cells and induces relaxation of coronary vascular smooth muscle, resulting in increased CBF. In fact, nitric oxide physiologically stimulated vasodilation by activation of SERCA (4), which was induced by S-glutathiolation of SERCA (2, 3).
In conclusion, from the data presented here, targeting for SERCA2a may be a potential therapeutic strategy for chronic DM-induced heart failure. The overexpression of SERCA2a clearly decreased cardiomyocyte size but not the amount of fibrosis. It is interesting to contrast our results with those targeting the protein phospatase 1 inhibitor-1 protein (upstream of the SERCA2a-phospholamban complex), which resulted in both a decrease in cardiac hypertrophy and fibrosis (14) . It seems that targeting SERCA2a may improve contractility, energetics, and coronary flow and may induce regression of myocyte hypertrophy but not induce regression of fibrosis at least in the short term (14) . Long-term expression studies, using adeno-associated vectors, are required to assess whether in the long-term SERCA2a will maintain its beneficial effects and alter even fibrosis.
